03. Discover RENAsym®
About RENAsym® Consortium

The RENAsym Consortium is a pre-competitive partnership between Simulations Plus and the pharmaceutical industry centered around the development of the RENAsym simulation tool. RENAsym is a mechanistic, mathematical model of drug-induced kidney injury, in the form of computational software applied to predict whether new drug candidates will cause renal injury signals in patients and to enhance the understanding of mechanisms that contribute to renal safety signals already observed in the clinic.

The consortium goals, much like those of the parallel DILI-sim Initiative, are to improve patient safety, reduce the need for animal testing, and reduce the costs and time necessary to develop new drugs.  Now, one membership fee covers your membership in the DILI-sim Initiative and RENAsym Consortium, as well as access to deliverables from both!

RENAsym v1A Summary Diagram

Members of the DILI-sim Initiative and RENAsym Consortium, which are covered under a joint membership agreement and annual fee, are provided the software deliverables below, along with training and access to the DSSI team for support, during their membership term:

  • 2 global floating licenses to each software platform (DILIsym and RENAsym)
  • Access to the high-performance grid license (HPGL) for both platforms upon release, which allows for scaling up simulation capabilities to an unlimited number of computational nodes.
  • 10 free customized training hours per software tool
  • Discounted or free attendance at workshops and courses
  • A substantial discount on consulting services related to DILIsym and RENAsym
  • Much, much more!

RENAsym v2A is the latest version of RENAsym, the gold standard in kidney safety prediction. Included in this release are…

  • NEW representation of the podocyte and distal tubule epithelial cells for predictions of acute kidney injury beyond the proximal tubule
  • NEW FDA-qualified biomarkers, including NAG, NGAL, and clusterin
  • NEW compounds added, including doxorubicin, polymyxin B, and lithium
  • NEW SimPops to better predict variability in toxicity mechanisms
  • UPDATED model of crystal nephropathy for better modeling of drug-induced crystal formation
04. Experts
Meet the Experts
Jeffrey Woodhead

Jeffrey Woodhead

Senior Principal Scientist
Quantitative Systems Pharmacology

Simulations Plus Forms Scientific Advisory Board for RENAsym Consortium.

04. Events
Upcoming Events
05. RENAsym® Resources
Peer-reviewed Publications